BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16925945)

  • 1. Ubiquitin pathway in VHL cancer syndrome.
    Ohh M
    Neoplasia; 2006 Aug; 8(8):623-9. PubMed ID: 16925945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA; Ohh M
    Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.
    Kaelin WG
    Biochem Biophys Res Commun; 2005 Dec; 338(1):627-38. PubMed ID: 16153592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.
    Chung J; Roberts AM; Chow J; Coady-Osberg N; Ohh M
    Oncogene; 2006 May; 25(21):3079-83. PubMed ID: 16407835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
    Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
    Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
    Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
    Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
    Haase VH
    Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
    Lewis MD; Roberts BJ
    Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Von Hippel-Lindau disease].
    Shuin T; Ashida S; Yao M; Kanno H
    Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.